A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma Buenos Aires, C1284AEB, Argentina
Nanjing, 210008, China
Wiesbaden, 65199, Germany
Naples, Campania 80131, Italy
Meldola, Emilia-Romagna 47014, Italy
Bunkyō City, 113-8677, Japan
Toyoake-shi, 470-1192, Japan
Gda?sk, 80-214, Poland
Moscovskaya Oblast, Moscow Oblast 143423, Russia
Moscow, Moscow Oblast 105229, Russia
Saint Petersburg, Sankt-Peterburg 197758, Russia
Jeollanam-do, 58128, South Korea
Santiago de Compostela, LA Coruna 15706, Spain
Adana, 01230, Turkey (Türkiye)
Edirne, 22770, Turkey (Türkiye)
Istanbul, 34890, Turkey (Türkiye)
Kar??yaka, 35575, Turkey (Türkiye)
Sihhiye/Ankara, 06230, Turkey (Türkiye)